Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HINT1 | P49773 | 1/20 | 0.45 |
| ▸ | POLA1 | P09884 | 1/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.44 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9548609 | 1.00 | POLB (0.52) | POLBKDM4EHPGDHINT1POLA1 | |
| SCHEMBL31098008 | 0.93 | POLB (0.51) | POLBKDM4EHPGDHINT1P2RY2 | |
| SCHEMBL889617 | 0.92 | POLB (0.51) | POLBKDM4EHPGDHINT1P2RY2 | |
| SCHEMBL14789008 | 0.92 | POLB (0.51) | POLBKDM4EHPGDHINT1P2RY2 | |
| SCHEMBL7613803 | 0.90 | POLB (0.51) | POLBKDM4EHPGDHINT1P2RY2 | |
| SCHEMBL1514931 | 0.90 | POLB (0.51) | POLBKDM4EHPGDHINT1P2RY2 | |
| SCHEMBL12570242 | 0.90 | POLB (0.51) | POLBKDM4EHPGDHINT1P2RY2 | |
| SCHEMBL31098077 | 0.89 | POLB (0.47) | POLBKDM4EHPGDHINT1STING1 | |
| SCHEMBL25070783 | 0.89 | POLB (0.53) | POLBKDM4EHPGDHINT1POLA1 | |
| SCHEMBL3279868 | 0.88 | POLB (0.56) | POLBKDM4EHPGDHINT1POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-03 | — | — | US | disclosed |
| US-20210171565-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20210147466-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF | TEVA CZECH INDUSTRIES S.R.O. (CZ) | 2021-05-20 | — | — | US | disclosed |
| EP-3797782-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | Janssen BioPharma, Inc. (US) | 2021-03-31 | — | — | EP | disclosed |
| WO-2019014286-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF | TEVA CZECH INDUSTRIES S.R.O. (CZ) | 2019-01-17 | — | — | WO | disclosed |
| EP-3424938-A1 | 4'-AZIDOALKYL-SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Alios Biopharma, Inc. (US) | 2019-01-09 | — | — | EP | disclosed |
| US-5192749-A | Viricide, AIDS | SYNTEX (U.S.A.) INC. (US) | 1993-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | POLB 16/4885KDM4E 684/4885HPGD 3566/4885 |
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | POLB 906/4885KDM4E 2160/4885HPGD 1860/4885 |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | POLB 906/4885KDM4E 2160/4885HPGD 1860/4885 |
| US-20210171565-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | POLB 906/4885KDM4E 2160/4885HPGD 1860/4885 |
| US-20210147466-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF | UNG, SAMHD1, ALKBH1 | POLB 29/4885KDM4E 604/4885HPGD 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.